Re: Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-Label, Single-Arm, Multicentre, Phase 2 Study

A. V. Balar; A. M. Kamat; G. S. Kulkarni; E. M. Uchio; J. L. Boormans; M. Roumiguié; L. E.M. Krieger; E. A. Singer; D. F. Bajorin; P. Grivas; H. K. Seo; H. Nishiyama; B. R. Konety; H. Li; K. Nam; E. Kapadia; T. Frenkl; R. De Wit

doi:10.1097/JU.0000000000002713

Re: Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-Label, Single-Arm, Multicentre, Phase 2 Study

A. V. Balar, A. M. Kamat, G. S. Kulkarni, E. M. Uchio, J. L. Boormans, M. Roumiguié, L. E.M. Krieger, E. A. Singer, D. F. Bajorin, P. Grivas, H. K. Seo, H. Nishiyama, B. R. Konety, H. Li, K. Nam, E. Kapadia, T. Frenkl, R. De Wit

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	212
Number of pages	1
Journal	Journal of Urology
Volume	208
Issue number	1
DOIs	https://doi.org/10.1097/JU.0000000000002713
Publication status	Published - 1 Jul 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/JU.0000000000002713

Cite this

Balar, A. V., Kamat, A. M., Kulkarni, G. S., Uchio, E. M., Boormans, J. L., Roumiguié, M., Krieger, L. E. M., Singer, E. A., Bajorin, D. F., Grivas, P., Seo, H. K., Nishiyama, H., Konety, B. R., Li, H., Nam, K., Kapadia, E., Frenkl, T., & De Wit, R. (2022). Re: Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-Label, Single-Arm, Multicentre, Phase 2 Study. Journal of Urology, 208(1), 212. https://doi.org/10.1097/JU.0000000000002713

@article{b221f5266e444896907c6a5982a65d65,

title = "Re: Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-Label, Single-Arm, Multicentre, Phase 2 Study",

author = "Balar, {A. V.} and Kamat, {A. M.} and Kulkarni, {G. S.} and Uchio, {E. M.} and Boormans, {J. L.} and M. Roumigui{\'e} and Krieger, {L. E.M.} and Singer, {E. A.} and Bajorin, {D. F.} and P. Grivas and Seo, {H. K.} and H. Nishiyama and Konety, {B. R.} and H. Li and K. Nam and E. Kapadia and T. Frenkl and {De Wit}, R.",

year = "2022",

month = jul,

day = "1",

doi = "10.1097/JU.0000000000002713",

language = "English",

volume = "208",

pages = "212",

journal = "Journal of Urology",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "1",

}

Balar, AV, Kamat, AM, Kulkarni, GS, Uchio, EM, Boormans, JL, Roumiguié, M, Krieger, LEM, Singer, EA, Bajorin, DF, Grivas, P, Seo, HK, Nishiyama, H, Konety, BR, Li, H, Nam, K, Kapadia, E, Frenkl, T & De Wit, R 2022, 'Re: Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-Label, Single-Arm, Multicentre, Phase 2 Study', Journal of Urology, vol. 208, no. 1, pp. 212. https://doi.org/10.1097/JU.0000000000002713

Re: Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-Label, Single-Arm, Multicentre, Phase 2 Study. / Balar, A. V.; Kamat, A. M.; Kulkarni, G. S. et al.
In: Journal of Urology, Vol. 208, No. 1, 01.07.2022, p. 212.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Re: Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057)

T2 - An Open-Label, Single-Arm, Multicentre, Phase 2 Study

AU - Balar, A. V.

AU - Kamat, A. M.

AU - Kulkarni, G. S.

AU - Uchio, E. M.

AU - Boormans, J. L.

AU - Roumiguié, M.

AU - Krieger, L. E.M.

AU - Singer, E. A.

AU - Bajorin, D. F.

AU - Grivas, P.

AU - Seo, H. K.

AU - Nishiyama, H.

AU - Konety, B. R.

AU - Li, H.

AU - Nam, K.

AU - Kapadia, E.

AU - Frenkl, T.

AU - De Wit, R.

PY - 2022/7/1

Y1 - 2022/7/1

UR - http://www.scopus.com/inward/record.url?scp=85132974071&partnerID=8YFLogxK

U2 - 10.1097/JU.0000000000002713

DO - 10.1097/JU.0000000000002713

M3 - Comment/Letter to the editor

C2 - 35440150

AN - SCOPUS:85132974071

SN - 0022-5347

VL - 208

SP - 212

JO - Journal of Urology

JF - Journal of Urology

IS - 1

ER -

Re: Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-Label, Single-Arm, Multicentre, Phase 2 Study

UN SDGs

Access to Document

Other files and links

Cite this